Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9 (D10A) nickase-mediated Hb CS gene editing and genetically modified fibroblast identification.

Bioengineered - 1 May 2022

Wu Wei-Hao, Ma Xiao-Mei, Huang Jian-Qing, Lai Qin, Jiang Fu-Neng, Zou Cui-Yun, Chen Long-Tian, Yu Lian

Abstract excerpt

This study investigated whether CRISPR/Cas9 (D10A) nickase-mediated gene editing can correct the aberrant Hb Constant Spring mutation (Hb CS or HBA2: c.427 T > C) in fibroblasts. Vectors for repairing the α-globin-encoding gene, HBA2:c.427 T > C mutation, includingthe CRISPR/Cas9(D10A)-sg plasmid and donor with homology arms, were constructed and used to perform gene editing in patient-derived fibroblasts. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Deoxyribonuclease I

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fibroblasts

Share to Gene Editing

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36700476
DOI: 10.1080/21655979.2022.2069940
PMCID: PMC9276056

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9 (D10A) nickase-mediated Hb CS gene editing and genetically modified fibroblast identification.PMID 36700476Read ↗

A Universal Approach to Target Various HBB Gene Mutations in Hematopoietic Stem/Progenitor Cells for Beta-Thalassemia Gene Therapy by CRISPR/Cas9 and the rAAV6 VectorSemantic proximity Read ↗

Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donorsSemantic proximity Read ↗

Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathiesSemantic proximity Read ↗

Efficient repair of human homozygous genetic mutation by CRISPR/Cas9 mediated interlocus gene conversionSemantic proximity Read ↗

Development of Gene Editing Strategies for Human <b>β</b> -Globin (HBB) Gene MutationsSemantic proximity Read ↗

CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation.Semantic proximity Read ↗

Investigating the Efficacy of the CRISPR/Cas9 Gene-Editing System for Targeting the HBB FSC 36-37 (-T) Mutation Locus in Hematopoietic Stem Cells.Semantic proximity Read ↗

Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.Semantic proximity Read ↗

New applications of CRISPR/Cas9 system on mutant DNA detection.Semantic proximity Read ↗

Development of gene editing strategies for human β-globin (HBB) gene mutations.Semantic proximity Read ↗

CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.Semantic proximity Read ↗

Gene Editing for Inherited Red Blood Cell DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.